Analytical and Bioanalytical Electrochemistry

Analytical and Bioanalytical Electrochemistry

A Review: Nanomaterial-Based Bio-Interfaces for Cardiac Biomarker Myoglobin Electrochemical Biosensing

Document Type : Review

Authors
1 Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
2 Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 Department of Laboratory Sciences, Sirjan School of Medical Sciences, Sirjan, Iran
4 Essential Oils Research Institute, University of Kashan, Postcode: 87317-51167, Kashan [Qamsar], I. R. Iran
5 Department of Biochemistry and Hematology, Faculty of Medicine Semnan University of Medical Sciences, Semnan, Iran
6 Physiology Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran
7 Faculty of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran
Abstract
Detecting cardiovascular disease [CVD] at its earliest stage is vital to effectively manage patients and improve their chances of full recuperation. Currently, identifying CVD during its initial development has become a significant concern for global health. The remarkable attributes of nanoscale electrochemical biosensors make them highly appropriate for detecting CVD biomarkers in bodily fluids even in extremely low quantities.  The unique advantages of biosensors that use electrochemistry, which include increased sensitivity and stability through electrode surface nanostructuring, as well as bioreceptors with heightened affinity and selectivity, have prompted exploration of new electrochemical biosensing techniques as viable alternatives to traditional methods for clinical diagnosis of cardiovascular disease.  In this review, current information on electrochemical biosensing techniques and signal amplification tactics employing nanomaterials for detecting myoglobin, a biomarker for cardiovascular disease, is presented. Future research efforts must prioritize the discovery of new, specific biomarkers for cardiovascular disease. Additionally, it is crucial to develop real-time analysis techniques for these biomarkers, as well as point-of-care validation assays that have excellent selectivity and sensitivity.
Keywords

Subjects


Volume 16, Issue 8 - Serial Number 8
August 2024
Pages 786-808

  • Receive Date 02 June 2024
  • Revise Date 18 August 2024
  • Accept Date 20 August 2024